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Introduction
Pyogenic arthritis, pyoderma gangrenosum, and acne
(PAPA) syndrome is an autosomal dominant autoinflam-
matory disease caused by mutations in the proline-serine-
threonine phosphatase-interacting protein 1, PSTPIP1.
The produced protein is a cytoskeleton-associated adap-
tor protein that modulates T-cell activation, cytoskeletal
organization and IL-1b release.
The only two mutations described so far, A230T and
E250Q, have been found in patients and families, and are
thought to disrupt the binding of PSTPIP1 with PTP-
PEST, a regulatory phosphatase, and increase its avidity
for pyrin in the cytosol, thereby dysregulating IL-1b
production. PAPA syndrome typically presents with recur-
rent sterile, erosive arthritis in childhood, resulting in sig-
nificant joint destruction. By puberty, joint problems tend
to subside and cutaneous symptoms increase including
pathergy, frequently with abscesses at the sites of injec-
tions, severe cystic acne, and recurrent non-healing sterile
ulcers, often diagnosed as pyoderma gangrenosum.
Case Report
We describe a a four year old Jordanian male, born to
healthy non-consanguineous parent, who presented with
cutaneous abscesses at the age of 6 months and then at
18 months at the vaccination injection sites. At the age of
20 months he developed cellulitis. At the age of 23 months,
he had acute arthritis of the right ankle. He developed
acute arthritis of the left wrist at 24 months, and the right
wrist at 27 months and then the right elbow at the age of
45 months. He has two older sisters and the family history
is negative for similar conditions. The sequencing of the
coding region of PSTPIP1 and flanking intronic regions
revealed a de novo variation p.Asp246Asn (p.D246N) in the
child. The variant is predicted to be probably damaging by
Polyphen and was not found in 360 ethnically-matched
control chromosomes.
Discussion
We describe a 4 year old Jordanian boy with a typical clin-
ical presentation of PAPA syndrome, with the exception
of the absence of pyoderma gangrenosum and acne.
However, both these findings may occur later in the
course of the disease, mostly after puberty. We anticipate
that this variation is the mutation the explains the symp-
toms in this child since it falls within the coiled coil
domain that harbors all the previously described muta-
tions. Since the E250Q and A230T variants of PSTPIP1
were shown to severely abrogate binding to PTP-PEST in
yeast two hybrid and co-immunoprecipitation experi-
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